TY - JOUR
T1 - New targets for Zika Virus determined by human-viral interactomic
T2 - a bioinformatics approach
AU - Esteves, Eduardo
AU - Rosa, Nuno
AU - Correia, Maria José
AU - Arrais, Joel P.
AU - Barros, Marlene
N1 - Funding Information:
This work was made possible by the support of Centre for Interdisciplinary Research in Health through funds from the FCT (Portuguese National Funding Agency for Science, Research, and Technology) granted to Unit 4279 (UID/MULTI/4279/2016) and by the support of SalivaTec through Mais CENTRO: Programa Operacional Regional do Centro under the Quadro de Referência Estratégico Nacional (QREN) and through the Fundo Europeu deDesenvolvimento Regional (FEDER) (CENTRO-07-CT62-FEDER-005004).
Funding Information:
This work was made possible by the support of Centre for Interdisciplinary Research in Health through funds from the FCT (Portuguese National Funding Agency for Science, Research, and Technology) granted to Unit 4279 (UID/MULTI/4279/2016) and by the support of SalivaTec through Mais CENTRO: Programa Operacional Regional do Centro under the Quadro de Referência Estratégico Nacional (QREN) and through the Fundo Europeu de Desen-volvimento Regional (FEDER) (CENTRO-07-CT62-FEDER-005004).
Publisher Copyright:
© 2017 Eduardo Esteves et al.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Identifying ZIKV factors interfering with human host pathways represents a major challenge in understanding ZIKV tropism and pathogenesis. The integration of proteomic, gene expression and Protein-Protein Interactions (PPIs) established between ZIKV and human host proteins predicted by the OralInt algorithm identified 1898 interactions with medium or high score (≥0.7). Targets implicated in vesicular traffic and docking were identified. New receptors involved in endocytosis pathways as ZIKV entry targets, using both clathrin-dependent (17 receptors) and independent (10 receptors) pathways, are described. New targets used by the ZIKV to undermine the host's antiviral immune response are proposed based on predicted interactions established between the virus and host cell receptors and/or proteins with an effector or signaling role in the immune response such as IFN receptors and TLR. Complement and cytokines are proposed as extracellular potential interacting partners of the secreted form of NS1 ZIKV protein. Altogether, in this article, 18 new human targets for structural and nonstructural ZIKV proteins are proposed. These results are of great relevance for the understanding of viral pathogenesis and consequently the development of preventive (vaccines) and therapeutic targets for ZIKV infection management.
AB - Identifying ZIKV factors interfering with human host pathways represents a major challenge in understanding ZIKV tropism and pathogenesis. The integration of proteomic, gene expression and Protein-Protein Interactions (PPIs) established between ZIKV and human host proteins predicted by the OralInt algorithm identified 1898 interactions with medium or high score (≥0.7). Targets implicated in vesicular traffic and docking were identified. New receptors involved in endocytosis pathways as ZIKV entry targets, using both clathrin-dependent (17 receptors) and independent (10 receptors) pathways, are described. New targets used by the ZIKV to undermine the host's antiviral immune response are proposed based on predicted interactions established between the virus and host cell receptors and/or proteins with an effector or signaling role in the immune response such as IFN receptors and TLR. Complement and cytokines are proposed as extracellular potential interacting partners of the secreted form of NS1 ZIKV protein. Altogether, in this article, 18 new human targets for structural and nonstructural ZIKV proteins are proposed. These results are of great relevance for the understanding of viral pathogenesis and consequently the development of preventive (vaccines) and therapeutic targets for ZIKV infection management.
UR - http://www.scopus.com/inward/record.url?scp=85042147818&partnerID=8YFLogxK
U2 - 10.1155/2017/1734151
DO - 10.1155/2017/1734151
M3 - Article
C2 - 29379794
AN - SCOPUS:85042147818
SN - 2314-6133
VL - 2017
JO - BioMed Research International
JF - BioMed Research International
M1 - 1734151
ER -